Zevra Therapeutics, Inc. (ZVRA)
ZVRA moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ZVRA actually reacts to news — the realized, point-in-time move the market made, measured across 338 labeled events over the last three years with zero look-ahead.
ZVRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.15% | 56% | 336 |
| 30-min | 0.00% | 49% | 337 |
| 60-min | 0.00% | 49% | 338 |
| to close | 0.00% | 49% | 333 |
| Middle 50% of ZVRA reactions | -1.04% to +1.05% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 338 |
Half of all Zevra Therapeutics, Inc. news events land between -1.04% and +1.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ZVRA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 17 | +0.47% | 77% | +0.13% |
| Rating reiterations | 78 | +0.89% | 73% | +0.80% |
| Price-target raises | 13 | +1.59% | 69% | +1.60% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ZVRA ranks against every other measured name →
That’s how ZVRA usually reacts — get an email when it moves on news →Email me when ZVRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ZVRA's baseline. Nothing else.
Recent ZVRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Zevra Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.91% | +1.91% | |
| Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium | Press release | GlobeNewswire | +1.10% | +1.95% | |
| Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.98% | -2.10% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -0.96% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.09% | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.22% | — | |
| Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +3.13% | |
| Form 10-Q ZEVRA THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.51% | +1.11% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +1.11% | |
| Zevra Reports Second Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +0.51% | +1.11% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.10% | +2.63% | |
| Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference | Press release | GlobeNewswire | -0.39% | +2.83% | |
| Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) | Press release | GlobeNewswire | +0.89% | +5.73% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.89% | +5.73% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.47% | -1.55% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.41% | +0.62% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.31% | +0.10% | |
| ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -1.12% | -0.81% | |
| Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | Press release | GlobeNewswire | +3.34% | +4.33% | |
| Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call | Press release | GlobeNewswire | -0.16% | -2.25% | |
| Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) | Press release | GlobeNewswire | +0.16% | +2.69% | |
| Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition | Press release | GlobeNewswire | -0.72% | -2.19% | |
| Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA | Press release | GlobeNewswire | +0.56% | +12.88% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +12.88% | |
| Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.99% | -0.86% | |
| Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference | Press release | GlobeNewswire | +1.32% | +0.91% | |
| Form 10-Q ZEVRA THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.06% | +1.29% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | +1.29% | |
| Zevra Reports First Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +1.06% | +1.29% | |
| Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call | Press release | GlobeNewswire | -0.90% | -0.38% | |
| Form DEF 14A ZEVRA THERAPEUTICS, INC. For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.66% | +1.03% | |
| Form PRE 14A ZEVRA THERAPEUTICS, INC. For: Apr 06 | SEC filing · Form PRE | SEC EDGAR | -0.21% | +3.62% | |
| Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.22% | +1.84% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +1.63% | -5.19% | |
| Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | Press release | GlobeNewswire | +1.63% | -5.19% | |
| Form 10-K ZEVRA THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.32% | +1.00% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +1.32% | +1.00% | |
| Form S-8 ZEVRA THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | +1.32% | +1.00% | |
| Zevra Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +1.32% | +1.00% | |
| Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer | Press release | GlobeNewswire | +0.79% | -1.01% | |
| Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call | Press release | GlobeNewswire | +1.48% | +3.41% | |
| Zevra Therapeutics to Present at the Citizens Life Sciences Conference | Press release | GlobeNewswire | +0.67% | -0.78% | |
| Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ | Press release | GlobeNewswire | -0.38% | -2.83% | |
| Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | Press release | GlobeNewswire | +0.67% | +4.70% | |
| Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ | Press release | GlobeNewswire | -1.12% | +1.01% | |
| Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference | Press release | GlobeNewswire | +1.54% | +2.37% | |
| Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) | Press release | GlobeNewswire | +0.80% | +0.34% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -1.22% | |
| Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | -2.51% | |
| Form 8-K ZEVRA THERAPEUTICS, INC. For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | -1.69% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ZVRA section they belong to.
Where else ZVRA is measured.
ZVRA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Zevra Therapeutics, Inc.'s median reaction calculated?
Every labeled ZVRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 338 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of ZVRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ZVRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.